The agreed upon use of income dividends or capital gains distributions for
the purchase of additional shares in a fund or company.
With a DRIP, you can reinvest the dividends that you earn back into the company that you own stock in, through
the purchase of additional shares of stock in the company.
Of course, if Mr. Market offers me a further 30 or 40 % discount over current prices I may have a hard time resisting
the purchase of additional shares.
An offer given to current shareholders allowing
the purchase of additional shares or securities before it's offered to the public.
Many people believe that reinvested mutual fund dividends are simply taxable income and don't see them as
a purchase of additional shares.
The DRIP allows shareholders to compound their investment through the convenient automatic
purchase of additional shares without incurring commissions.
3) Since they're not on automatic investing, I can re-balance my portfolio monthly through
my purchasing of additional shares of one ETF and not as many in another
Not exact matches
HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing
of its previously announced underwritten public offering
of 9,200,000
shares of its common stock, including 1,200,000
shares sold pursuant to the underwriters» full exercise
of their option to
purchase additional shares, at a public offering price
of $ 7.50 per
share.
«However, Berkshire routinely assesses market conditions and may decide to
purchase additional shares of common stock
of Wells Fargo based on its evaluation
of the investment opportunity presented by such
purchases.»
Bellicum expects to grant the underwriters
of the offering a 30 - day option to
purchase up to an
additional 1,050,000
shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Pursuant to the offering, Centene granted the underwriters an option to
purchase from the Company up to an
additional $ 260 million in
shares of common stock.
Charoen gained the upper hand when he amassed a stake
of more than 40 percent in F&N by
purchasing an
additional 90.8 million
shares, or a 6.3 percent stake in F&N, at S$ 9.55 each on Friday and another 2.2 million
shares on Saturday.
There were also employee
share options outstanding to
purchase up to an
additional 3.4 million
shares, at a weighted average exercise price
of $ 31.37 per
share, 0.8 million
of which were fully vested; equity - settled
share appreciation rights (SARs) for 0.2 million
shares, at a weighted average measurement price
of $ 32.18, all
of which, excluding SARs for approximately 1,000
shares, were fully vested; and restricted
share units (RSUs) covering 13.0 million
shares,
of which RSUs to acquire 4.3 million
shares were fully vested.
Should the deal's underwriters exercise an option to
purchase up to 2.4 million
additional shares, Ardagh said it could raise as much as $ 372.6 million (352.2 million euros) at the top
of its price range.
DALLAS, April 19, 2017 / PRNewswire / — NexPoint Credit Strategies Fund (NYSE: NHF)(the «Fund») today announced the commencement
of a non-transferable rights offering to
purchase additional shares of common stock
of the Fund (the «Offering») as the Fund's registration statement has been declared effective by the Securities and Exchange Commission.
In connection with the acquisition
of XA Secure, the Company also issued 265,012
shares of restricted stock, issued 318,966 options to
purchase the Company's common stock and may be required to pay an
additional $ 3.92 million to certain key employee - shareholders
of XA Secure.
(d) by causing Retrophin to pay cash to himself, Biestek, and Fernandez so that he would not have to invest $ 731,778
of his own funds in the February PIPE, and by using PIPE proceeds in contravention
of the terms
of the Securities
Purchase Agreement to fund investments by Shkreli, Biestek and Fernandez, resulting in an
additional benefit to Shkreli alone
of $ 360,000 in cash and 180,000 Retrophin
shares and warrants worth more than $ 5.3 million (at current market prices).
In making this determination, the underwriters will consider, among other things, the price
of shares available for
purchase in the open market compared to the price at which the underwriters may
purchase shares through the option to
purchase additional shares.
The table above does not include (i) 5,952,917
shares of Class A common stock reserved for issuance under our 2015 Incentive Award Plan (as described in «Executive Compensation — New Employment Agreements and Incentive Plans»), consisting
of (x) 2,689,486
shares of Class A common stock issuable upon exercise
of options to
purchase shares of Class A common stock granted on the date
of this prospectus to our directors and certain employees, including the named executive officers, in connection with this offering as described in «Executive Compensation — Director Compensation» and «Executive Compensation — New Equity Awards,» and (y) 3,263,431
additional shares of Class A common stock reserved for future issuance and (ii) 24,269,792
shares of Class A common stock issuable to the Continuing SSE Equity Owners upon redemption or exchange
of their LLC Interests as described in «Certain Relationships and Related Party Transactions — SSE Holdings LLC Agreement.»
If any
additional shares of Class A common stock are
purchased, the underwriters will offer the
additional shares on the same terms as those on which the
shares are being offered.
You will experience
additional dilution when those holding options exercise their right to
purchase common stock under our equity incentive plans, when RSUs vest and settle, when we issue restricted stock to our employees under our equity incentive plans, or when we otherwise issue
additional shares of our common stock.
Except as otherwise indicated, the discussion and the tables above assume no exercise
of the underwriters» option to
purchase additional shares of Class A common stock.
The table assumes no exercise by the underwriters
of their option to
purchase additional shares of Class A common stock.
The adjustment assumes there will be no
additional distribution in the event the gross proceeds from the offering exceed the anticipated gross proceeds (including as a result
of the exercise by the underwriters
of their option to
purchase additional shares of Class A common stock).
The underwriters have 30 days from the date
of this prospectus to exercise this option to
purchase additional shares.
The Company's board
of directors also approved an
additional distribution to its members, to the extent the gross proceeds
of the Company's planned initial public offering exceed the anticipated gross proceeds (including as a result
of the exercise by the underwriters
of their option to
purchase additional shares of Class A common stock), in an amount equal to the product
of (A) the increased gross proceeds and (B) 0.273, to be paid from the proceeds
of the Company's planned initial public offering.
On the date the
shares subject to this offering are priced, each non-employee director who, as
of the date
of this offering, is serving on our board
of directors and is expected to continue his or her service following this offering will be granted (a) an option to
purchase shares of our Class A common stock with a grant date fair value
of $ 50,000 (or, if such director is unaffiliated with any significant stockholder
of the Company, $ 75,000) and (b) to the extent such director is (i) unaffiliated with any significant stockholder
of the Company and (ii) the chairman
of any committee
of our board
of directors, an
additional option to
purchase shares of our Class A common stock with a fair value
of $ 10,000 with respect to each such chairmanship.
The diagram below depicts our organizational structure immediately following this offering assuming no exercise by the underwriters
of their option to
purchase additional shares of Class A common stock.
Upon the completion
of this offering and after giving effect to the planned recapitalization
of our common stock into a single class
of common stock and stock split, SIH will own
shares of our outstanding common stock (representing %
of the
shares outstanding), our founders and their family trusts will own an aggregate
shares of our outstanding common stock (representing %
of the
shares outstanding) and our employees who received
shares upon the liquidation
of the special purpose employee ownership vehicle will own
shares of our outstanding common stock under a restricted stock award (representing %
of the
shares outstanding), in each case as it relates to the percentage ownership assuming that the underwriters do not exercise their option to
purchase additional shares.
Our principal stockholders, funds affiliated with or related to Cyrus Capital Partners, L.P. (which we refer to in this prospectus collectively as «Cyrus Capital») and affiliates
of Virgin Group Holdings Limited (which we refer to in this prospectus collectively as the «Virgin Group»), as selling stockholders, have granted the underwriters an option to
purchase up to
additional shares of common stock at the initial public offering price less the underwriting discount solely to cover overallotments.
Following the 2014 Recapitalization, we may have
additional outstanding warrants to
purchase shares of our common stock.
QS Investors LLC now owns 75,620
shares of the biopharmaceutical company's stock worth $ 2,358,000 after
purchasing an
additional 3,771
shares in the last quarter.
American International Group Inc. now owns 51,539
shares of the biopharmaceutical company's stock worth $ 1,607,000 after
purchasing an
additional 2,255
shares in the last quarter.
William Blair Investment Management LLC now owns 1,762,619
shares of the medical device company's stock worth $ 101,157,000 after
purchasing an
additional 344,294
shares in the last quarter.
The Company has granted the Agents an over-allotment option, exercisable in whole or in part, for a period
of 30 days following the closing
of the Offering, to
purchase up to an
additional 4,726,500 Units at $ 3.65 per Unit, 4,726,500 Common
Shares at the price
of $ 3.62 per
Share or 2,363,250 Warrants at the price
of $ 0.06 per Warrant, or any combination thereof.
Victory Capital Management Inc. now owns 485,087
shares of the insurance provider's stock valued at $ 33,422,000 after
purchasing an
additional 70,992
shares during the period.
Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662
shares of the biopharmaceutical company's stock worth $ 145,000 after
purchasing an
additional 2,698
shares in the last quarter.
AXA now owns 1,911,206
shares of the medical device company's stock worth $ 109,684,000 after
purchasing an
additional 592,275
shares in the last quarter.
OppenheimerFunds Inc. now owns 1,495,535
shares of the medical device company's stock worth $ 85,829,000 after
purchasing an
additional 734,325
shares in the last quarter.
The firm owned 20,436
shares of the insurance provider's stock after
purchasing an
additional 7,731
shares during the quarter.
Crestline Management LP now owns 68,856
shares of the biopharmaceutical company's stock worth $ 2,147,000 after
purchasing an
additional 3,437
shares in the last quarter.
Fisher Asset Management LLC now owns 11,872,530
shares of the payment services company's stock worth $ 1,179,061,000 after
purchasing an
additional 325,140
shares during the last quarter.
BlackRock Inc. now owns 43,090,501
shares of the payment services company's stock worth $ 4,279,318,000 after
purchasing an
additional 781,329
shares during the last quarter.
Geode Capital Management LLC now owns 7,700,608
shares of the payment services company's stock worth $ 763,153,000 after
purchasing an
additional 382,691
shares during the last quarter.
When you
purchase a dividend stock, you have the option
of getting your dividends paid out to you or reinvesting them in
additional shares.
Swiss National Bank now owns 119,600
shares of the biopharmaceutical company's stock worth $ 3,729,000 after
purchasing an
additional 2,800
shares in the last quarter.
Mackenzie Financial Corp now owns 1,371,595
shares of the medical device company's stock worth $ 78,716,000 after
purchasing an
additional 87,848
shares in the last quarter.
LPL Financial LLC now owns 47,874
shares of the company's stock worth $ 2,303,000 after
purchasing an
additional 15,441
shares during the period.
Ramsay Stattman Vela & Price Inc. now owns 84,028
shares of the conglomerate's stock worth $ 8,227,000 after
purchasing an
additional 550
shares in the last quarter.
FTB Advisors Inc. now owns 4,064
shares of the conglomerate's stock worth $ 386,000 after
purchasing an
additional 528
shares in the last quarter.